JeffreyArnoldMoscowMD

PubMed

• Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E.
  Monica F Chen, Zihe Song, Helena A Yu, Lecia V Sequist, Christine M Lovly, Edith P Mitchell, Jeffrey A Moscow, Robert J Gray, Victoria Wang, Lisa M McShane, Larry V Ru...> ;JCO Precision Oncology. 2024 Apr 1
• Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carc...
  Lim, K., Yige Wu, Siqi Chen, Xiaolu Yang, Kazuhito Sato, Preet Lal, Yuefan Wang, Andrew T Shinkle, Michael C Wendl, Tina M Primeau, Yanyan Zhao, Alanna Gould, Hua Sun,...> ;Cancer Research. 2023 Dec 15
• The potential to backfill in phase I trials: the National Cancer Institute's Cancer Therapy Evaluation Program experience.
  Jared C Foster, Edward L Korn, Boris Freidlin, Jeffrey A Moscow> ;JNCI Cancer Spectrum. 2023 Oct 31
• 1 citations
  The New NCI Precision Medicine Trials.
  Lyndsay N Harris, Charles D Blanke, Harry P Erba, James M Ford, Robert J Gray, Michael L LeBlanc, Siwen Hu-Lieskovan, Mark R Litzow, Selina M Luger, Funda Meric-Bernst...> ;Clinical Cancer Research. 2023 Dec 1
• 2 citations
  Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell L...
  Julio C Chavez, Francine M Foss, Basem M William, Jonathan E Brammer, Sonali M Smith, Anca Prica, Jasmine M Zain, Joseph M Tuscano, Harsh Shah, Neha Mehta-Shah, Pravee...> ;Clinical Cancer Research. 2023 May 15
• 11 citations
  National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH).
  Funda Meric-Bernstam, James M Ford, Peter J O'Dwyer, Geoffrey I Shapiro, Lisa M McShane, Boris Freidlin, Roisin E O'Cearbhaill, Suzanne George, Julia Glade-Bender, Gar...> ;Clinical Cancer Research. 2023 Apr 14
• Expanding access to early phase trials: the CATCH-UP.2020 experience.
  Joaquina C Baranda, Francisco J Diaz, Larry Rubinstein, Anthony F Shields, Farshid Dayyani, Amitkumar Mehta, Janice M Mehnert, Jonathan Trent, Rodwell Mabaera, Margare...> ;JNCI Cancer Spectrum. 2023 Jan 3
• 3 citations
  Dose optimization during drug development: whether and when to optimize.
  Edward L Korn, Jeffrey A Moscow, Boris Freidlin> ;Journal of the National Cancer Institute. 2023 May 8
• 7 citations
  Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group.
  Ami V Desai, Andrew L Gilman, Mehmet Fevzi Ozkaynak, Arlene Naranjo, Wendy B London, Sheena C Tenney, Mitchell Diccianni, Jacquelyn A Hank, Marguerite T Parisi, Barry ...> ;Journal of Clinical Oncology. 2022 Dec 10
• 5 citations
  Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molec...
  Philippe L Bedard, Shuli Li, Kari B Wisinski, Eddy S Yang, Sewanti A Limaye, Edith P Mitchell, James A Zwiebel, Jeffrey A Moscow, Robert J Gray, Victoria Wang, Lisa M ...> ;JCO Precision Oncology. 2022 Jul 1
• 5 citations
  PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery.
  Soner Koc, Michael W Lloyd, Jeffrey W Grover, Nan Xiao, Sara Seepo, Sai Lakshmi Subramanian, Manisha Ray, Christian Frech, John DiGiovanna, Phillip Webster, Steven Neu...> ;NAR Cancer. 2022 Jun 1
• 1 citations
  Author Correction: Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment.
  Hua Sun, Song Cao, R Jay Mashl, Chia-Kuei Mo, Simone Zaccaria, Michael C Wendl, Sherri R Davies, Matthew H Bailey, Tina M Primeau, Jeremy Hoog, Jacqueline L Mudd, Denn...> ;Nature Communications. 2022 Jan 7
• 48 citations
  Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment
  Hua Sun, Song Cao, R. Jay Mashl, Chia-Kuei Mo, Simone Zaccaria, Michael C. Wendl, Sherri R. Davies, Matthew H. Bailey, Tina Primeau, Jeremy Hoog, Jacqueline Mudd, Denn...> ;Nature Communications. 2021 Aug 24
• 4 citations
  Author Correction: Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts.
  Xing Yi Woo, Jessica Giordano, Anuj Srivastava, Zi-Ming Zhao, Michael Lloyd, Roebi de Bruijn, Yun-Suhk Suh, Rajesh Patidar, Li Chen, Sandra D. Scherer, Matthew H. Bail...> ;Nature Genetics. 2021 Feb 19
• 97 citations
  Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts.
  Xing Yi Woo, Jessica Giordano, Anuj Srivastava, Zi-Ming Zhao, Michael Lloyd, Roebi de Bruijn, Yun-Suhk Suh, Rajesh Patidar, Li Chen, Sandra D. Scherer, Matthew H. Bail...> ;Nature Genetics. 2021 Jan 7
• 17 citations
  Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903)
  Erin M. Bertino, Ryan D. Gentzler, Sarah E. Clifford, Jill M. Kolesar, Alona Muzikansky, Eric B. Haura, Zofia Piotrowska, D. Ross Camidge, Thomas E. Stinchcombe, Chris...> ;Clinical Cancer Research. 2021 Mar 15
• 24 citations
  A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal Melanoma
  Merve Hasanov, Matthew J. Rioth, Kari Kendra, Leonel Hernandez-Aya, Richard W. Joseph, Stephen K. Williamson, Sunandana Chandra, Keisuke Shirai, Christopher D. Turner,...> ;Cancers. 2020 Aug 13
• 2 citations
  Fumarate hydratase-deficient renal cell carcinoma cells respond to asparagine by activation of the unfolded protein response and stimulation of the hexosamine biosynth...
  Rony Panarsky, Daniel R. Crooks, Andrew N. Lane, Youfeng Yang, Teresa Cassel, Teresa W.-M. Fan, W. Marston Linehan, Jeffrey A. Moscow> ;Cancer & Metabolism. 2020 Aug 3
• 39 citations
  Phase II trial of the glycoprotein non-metastatic B-targeted antibody–drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report fro...
  Lisa M. Kopp, Suman Malempati, Mark Krailo, Yun Gao, Allen Buxton, Brenda J. Weigel, Thomas Hawthorne, Elizabeth Crowley, Jeffrey A. Moscow, Joel M. Reid, Victor M. Vi...> ;European Journal of Cancer. 2019 Nov 1
• 3 citations
  Transforming the Early Drug Development Paradigm at the National Cancer Institute: The Formation of NCI's Experimental Therapeutics Clinical Trials Network (ETCTN).
  Holly A. Massett, Grace Mishkin, Jeffrey A. Moscow, Amy E. Gravell, Michael Steketee, Martha Kruhm, Sae H Han, Barbara Barry, Michael Montello, James A. Zwiebel, Jeffr...> ;Clinical Cancer Research. 2019 Aug 22
• 8 citations
  Future Approaches to Precision Oncology-Based Clinical Trials.
  Arjun Mittra, Jeffrey A Moscow> ;Cancer Journal. 2019 Jul 1
• 17 citations
  A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab tr...
  Bora Lim, Rashmi Krishna Murthy, Jangsoon Lee, S. Jackson, Toshiaki Iwase, Darren W. Davis, Jie Willey, Jimin Wu, Yu Shen, Debu Tripathy, Ricardo H. Alvarez, Nuhad K. ...> ;British Journal of Cancer. 2019 May 17
• 1 citations
  Distinguishing mechanisms of adverse drug reactions from mechanisms of actions of drugs.
  Ting Hui Wu, Nagla Abdel Karim, Jeffrey A. Moscow> ;Oncotarget. 2018 Aug 21
• 96 citations
  The evidence framework for precision cancer medicine
  Jeffrey A. Moscow, Tito Fojo, Richard L. Schilsky> ;Nature Reviews. Clinical Oncology. 2018 Mar 1
• 27 citations
  Steps forward for cancer precision medicine.
  Roberto Salgado, Helen M. Moore, John W.M. Martens, Tracy Lively, Shakun Malik, Ultan McDermott, Stefan Michiels, Jeffrey A. Moscow, Sabine Tejpar, Tawnya C. McKee, De...> ;Nature Reviews. Drug Discovery. 2018 Jan 1
• Join now to see all